Deerfield Management Company, L.P. (Series C) Krystal Biotech, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 4,166 shares of KRYS stock, worth $630,399. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,166
Previous 1,605
159.56%
Holding current value
$630,399
Previous $294,000
157.48%
% of portfolio
0.01%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding KRYS
# of Institutions
311Shares Held
24.6MCall Options Held
503KPut Options Held
384K-
Black Rock Inc. New York, NY3.95MShares$597 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.88MShares$436 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$397 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$220 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$150 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $3.88B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...